The Beauty of Science: No Need to Think About Costs When You Live in An Ivory Tower

The recently published INSIGHT trial showed that starting HIV therapy earlier rather than later has benefit for patients 1. This should not come as a surprise considering the excellent suppressive power of current triple regimens.  The trial which enrolled 4685 HIV infected patients was stopped prematurely when an interim analysis Continue reading The Beauty of Science: No Need to Think About Costs When You Live in An Ivory Tower

The Etiology of CAP Remains Elusive – A Call to Change Antibiotic Prescribing Patterns

Once upon a time – not so long ago – we were taught the following: Streptococcus pneumoniae was the cause of 90% of CAP cases. That statement was later modified to mean S. pneumoniae was the underlying pathogen in 90% of bacterial cases of CAP, i.e., those with positive cultures from sputum or Continue reading The Etiology of CAP Remains Elusive – A Call to Change Antibiotic Prescribing Patterns

QIDP Drugs – 4th Edition

>>> For the latest QIDP list, please click HERE  <<< Since our last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table which includes compound, sponsor and development stage (Phase). It also indicates whether a drug has been the topic of a Continue reading QIDP Drugs – 4th Edition